相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
Rubens Barros Costa et al.
Oncotarget (2018)
ALK-rearrangement in non-small-cell lung cancer (NSCLC)
Xue Du et al.
THORACIC CANCER (2018)
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Irene Moya-Horno et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
C. G. Woo et al.
ANNALS OF ONCOLOGY (2017)
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Myung-Ju Ahn et al.
EXPERT OPINION ON DRUG SAFETY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
Paul Hofman
CANCERS (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
Lyudmila Bazhenova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
Antonio Passaro et al.
ONCOTARGETS AND THERAPY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
Dickran Kazandjian et al.
ONCOLOGIST (2014)
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia et al.
CLINICAL EPIDEMIOLOGY (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anaplastic lymphoma kinase: signalling in development and disease
Ruth H. Palmer et al.
BIOCHEMICAL JOURNAL (2009)
Translocations involving anaplastic lymphoma kinase (ALK)
J Duyster et al.
ONCOGENE (2001)
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
GE Stoica et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
